Phase 4
Completed N=74
Clinical Study of Generic and Brand Bupropion in Depression
Source: ClinicalTrials.gov NCT02209597 ↗Enrolled (actual)
74
Serious AEs
0.0%
Results posted
Apr 2020
Primary outcomePrimary: Area Under the Curve (AUC0-24) Ratio for Racemic Bupropion — .84; .88; .83; .89 percentage of Brand — p=<0.05
◆ Published Evidence
Emerging
3citations · ~2 / year
Pharmacogenetic Influence on Stereoselective Steady-State Disposition of Bupropion.
Summary
Determine bioequivalence between branded and generic bupropion extended release (XL) products (and between generic products) at steady state in patients with major depressive disorder.
Linked Publications
-
Pharmacogenetic Influence on Stereoselective Steady-State Disposition of Bupropion.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Area Under the Curve (AUC0-24) Ratio for Racemic Bupropion |
.84; .88; .83; .89; 20.9; 20.9 | <0.05 sig |
Eligibility Criteria
Inclusion Criteria
Each subject must meet all of the following criteria:
- Adult outpatients age 18-75 years
- Currently on once daily bupropion HCl 300mg XL (brand or any generic), for a minimum of 4 months
- Major depressive disorder (MDD), in partial or full remission for at least 4 months, as confirmed by the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID). Spontaneous relapse of depression unrelated to medication changes is less likely - about 5% chance per year - after remission has been maintained for at least 4 months.2
- Ability to understand and willingness to comply with study procedures, and to provide written informed consent
Exclusion Criteria
Subjects will not be enrolled if any of the following criteria exist:
- Remission from depression not clearly attributed to bupropion treatment
- Current severe side effects attributable to bupropion
- Poor adherence to bupropion treatment per patient self- report and history of refill persistence
- History of active seizure disorder, or seizure treatment within past year
- History of significant hepatic or renal disease, based on physician assessment
- Currently taking drugs or natural products known to influence cytochrome P450B6 (CYP2B6) activity
- Currently taking drugs for hepatitis C or multiple sclerosis, due to their ability to cause depression
- Dementia or other significant cognitive impairment, per diagnosis or investigative team's assessment
- Lifetime diagnosis of schizophrenia, schizoaffective or schizophreniform dis-order, delusional disorder, or current psychotic symptoms diagnosed by SCID
- Abuse of or dependence on alcohol or other substances within the past 6 months as determined by SCID, and confirmed by study physician interview
- Current suicidal ideation
Data sourced from ClinicalTrials.gov (NCT02209597) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.